PALTC23 Conference Recordings FR06 PALTC e-Prescribing: Upcoming Changes and Requirements

PALTC e-Prescribing: Upcoming Changes and Requirements

This session will review the upcoming regulatory changes impacting the LTC e-Prescribing environment including the SUPPORT Act’s electronic prescribing of controlled substances (EPCS) mandate and recent changes to the NCPDP e-Prescribing SCRIPT Standard to accommodate the three-party (prescriber, facility/caregiver, & pharmacy) communication needs of LTC. Pertinent DEA requirements surrounding EPCS will also be discussed.

Learning Objectives:

At the completion of this session, learners will be able to:

  • Discuss the unique challenges of electronic prescribing within the LTC segment and the solutions incorporated into the NCPDP SCRIPT e-Prescribing Standard to accommodate these challenges.
  • Summarize the SUPPORT Act’s electronic prescribing of controlled substances mandate and the corresponding compliance deadlines.
  • Describe current DEA requirements related to electronic prescribing of controlled substances.

Gary Schoettmer, RPh

Gary Schoettmer, RPh, is the Vice President of Government Affairs for Stone Arch LTC, a national buying group of independently owned LTC pharmacies. He has over 40 years experience in the LTC pharmacy industry. He is active with the National Council of Prescription Drug Programs (NCPDP) where he co-chairs their Long Term and Post Acute Care (LTPAC) Work Group and co-leads the NCPDP Consultant Pharmacist Interoperability Task Group. Mr. Schoettmer is chairman of the American Society of Consultant Pharmacists (ASCP) Government Affairs Committee, and serves on ASCP's Health IT Committee and ASCP's DEA Task Force. He is a member of the National Community Pharmacists Association (NCPA), participating in NCPA's LTC Division. He also serves on the Policy Council for the Senior Care Pharmacy Coalition, and is a former board member and past president of the American Society for Automation in Pharmacy. Mr. Schoettmer is a graduate of the Purdue University School of Pharmacy.

  • 1.0 CME
  • 1.0 CMD Management
  • 1.0 MOC

Release Date: 03/29/2023   |   Expiration: 03/01/2026

Credit Statements:

Accreditation: Post-Acute and Long-Term Care Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

CME Designation: Post-Acute and Long-Term Care Medical Association designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CMD Credit Hours: This CME activity has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for up to 1.0 management hour(s) toward certification or recertification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. Each physician should claim only those hours of credit actually spent on the activity.

The CMD Program is administered by the ABPLM. For further information, contact ABPLM at 410-992-3117 or at cmd@paltmed.org.

ABIM Maintenance of Certification (MOC): Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points and patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Financial Disclosure Statement:

The Association requires the disclosure of all speaker/faculty/planner’s relevant financial relationships; presence of off-label use of a device or medication; and discussion of any experimental, new or evolving topic prior to each accredited education activity.

If the learner perceives any bias toward a commercial product or service, advocation of unscientific approaches to diagnosis or therapy, or recommendation, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients please report this to the Association's staff.


The following speaker(s) disclosed relevant financial relationship(s): 

  • Julie Gammack, MD, CMD (Planner & Speaker): Stockholder: Amarin
  • Kenya Rivas Velasquez, MD, CMD, FAAFP (Planner & Speaker): OptumRx: Stockholder
  • All other planners, speakers, and AMDA staff have no relationships with ineligible companies.

All relevant financial relationships have been identified and mitigated.

Components visible upon registration.